Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial
Highlights
- • Everolimus eluting stents (EES) are superior to paclitaxel eluting stents (PES) in patients with diabetes.
- • However, it is not known if EES is as beneficial in patients with CKD compared with those without CKD.
- • Among the 1821 patients with diabetes included in the TUXEDO-India trial, 344 (19%) had CKD.
- • A significant interaction between CKD status and stent type (EES vs. PES) was noted for the outcomes of TVF, MACE, cardiac death or MI, non-target vessel related MI, non-Q-wave MI and deaths/MI/TVR such that EES was superior to PES in the non-CKD cohort but not in the CKD cohort.
Abstract
Background
Patients with diabetes and those with chronic kidney disease (CKD) are at increased risk of cardiovascular events. Everolimus eluting stents (EES) have been shown to be superior to paclitaxel eluting stents (PES) in patients with diabetes. However, it is not known if EES is as beneficial in diabetic patients with CKD compared with those without CKD.